bosentan anhydrous has been researched along with Diabetic Angiopathies in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ergul, A; Li, W; Sachidanandam, K | 1 |
| Böhm, F; Brismar, K; Gonon, A; Pernow, J; Rafnsson, A; Settergren, M | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Rumble, JR; van Eeden, P | 1 |
| Fedak, PW; Ko, L; Li, RK; Li, SH; Maitland, A; Mickle, DA; Pomroy, NC; Rao, V; Verma, S; Weisel, RD | 1 |
1 trial(s) available for bosentan anhydrous and Diabetic Angiopathies
| Article | Year |
|---|---|
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
Topics: Aged; Albuminuria; Antihypertensive Agents; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Microvessels; Middle Aged; Peripheral Vascular Diseases; Severity of Illness Index; Sulfonamides; Vasodilation | 2012 |
3 other study(ies) available for bosentan anhydrous and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2011 |
Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
Topics: Animals; Antihypertensive Agents; Blotting, Northern; Bosentan; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin Receptor Antagonists; Endothelium, Vascular; Epidermal Growth Factor; Extracellular Matrix; Gene Expression; Hypertrophy; In Situ Hybridization; Male; Mast Cells; Mesenteric Arteries; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides | 2000 |
Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism.
Topics: Antihypertensive Agents; Bosentan; Cells, Cultured; Diabetic Angiopathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Myocardial Reperfusion Injury; Peptides, Cyclic; Sulfonamides | 2002 |